Adamis Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Adamis Pharmaceuticals generated cash of -$25,900,506, which is more than the previous year. Cash used in financing activities reached the amount of $285,000 last year. Net change in cash is therefore -$22,139,361.
Cash Flow
| 2013 | -2.55M | 0 | 2.55M |
|---|---|---|---|
| 2014 | -6.78M | -10M | 22.18M |
| 2015 | -10.33M | 0 | 10.64M |
| 2016 | -21.16M | 260.74K | 21.91M |
| 2017 | -15.13M | -2.08M | 30.45M |
| 2018 | -32.65M | -3.53M | 37.13M |
| 2019 | -19.88M | -2.86M | 12.29M |
| 2020 | -20.90M | -946.21K | 19.89M |
| 2021 | -37.78M | 282.73K | 53.93M |
| 2022 | -25.90M | 3.48M | 285K |
ADMP Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 23.25M | 6.74M | 8.81M | 19.27M | 18.33M | 5.09M | 4.08M | 3.77M | 0 | 7.51K |
Operating activities | ||||||||||
Net income | -26.47M | -45.82M | -49.39M | -29.30M | -39.00M | -25.53M | -19.43M | -13.57M | -8.15M | -7.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.48M | 1.43M | 3.60M | 2.94M | 3.09M | 3.06M | 2.53M | 990.29K | 296.12K | 0 |
Stock-based compensation expense | -340.27K | 1.98M | 4.42M | 5.86M | 6.53M | 6.05M | 4.75M | 2.51M | 596.09K | 164.50K |
| Deferred income tax benefit | -340.27K | 1.98M | 4.42M | 5.86M | 6.53M | 6.05M | 4.75M | 2.51M | 596.09K | 164.50K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -238.49K | -573.34K | 737.93K | -745.14K | -421.01K | -87.62K | -363K | 0 | 0 | 0 |
Inventories | -820.17K | -236.15K | -3.41M | 24.76K | -4.98M | -882.49K | 1.89K | 0 | 0 | 0 |
Accounts payable | 3.93M | 1.90M | -726.70K | 574.51K | 846.12K | 587.15K | -1.70M | -289.21K | -1.76M | 411.20K |
Cash generated by operating activities | -25.90M | -37.78M | -20.90M | -19.88M | -32.65M | -15.13M | -21.16M | -10.33M | -6.78M | -2.55M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -680.41K | -1.22M | -946.21K | -2.86M | -3.53M | -2.08M | -121.10K | 0 | -10M | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 381.88K | 0 | 0 | 0 |
Cash generated by investing activities | 3.48M | 282.73K | -946.21K | -2.86M | -3.53M | -2.08M | 260.74K | 0 | -10M | 0 |
Financing activities | ||||||||||
Common Stock Issued | 300K | 51.74M | 18.22M | 12.78M | 37.61M | 16.02M | 10.21M | 10.56M | 25.45M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -90.62K | 0 | -487.90K | 0 | -324.64K | 0 | -6.93M | -548.31K |
Cash used in financing activities | 285K | 53.93M | 19.89M | 12.29M | 37.13M | 30.45M | 21.91M | 10.64M | 22.18M | 2.55M |
Net Change In Cash | -22.13M | 16.50M | -1.95M | -10.46M | 938.94K | 13.23M | 1.01M | 305.98K | 5.40M | -7.51K |
Cash at end of period | 1.11M | 23.25M | 6.85M | 8.81M | 19.27M | 18.33M | 5.09M | 4.08M | 5.40M | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |